相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany
Monika Engelhardt et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples
Ruixuan Jiang et al.
QUALITY OF LIFE RESEARCH (2021)
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the United States
Deepu Madduri et al.
FUTURE ONCOLOGY (2021)
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect(R) MM Registry
Rafat Abonour et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Treatment Options for Triple-class Refractory Multiple Myeloma
Joseph Mikhael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial et al.
LANCET ONCOLOGY (2020)
Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France
Nicolas Despiegel et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H. Gandhi et al.
LEUKEMIA (2019)
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Unplanned Hospitalization Among Individuals With Cancer in the Year After Diagnosis
Robin L. Whitney et al.
JOURNAL OF ONCOLOGY PRACTICE (2019)
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
Inger S. Nijhof et al.
DRUGS (2018)
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
S. K. Kumar et al.
LEUKEMIA (2017)
Novel agents in the treatment of multiple myeloma: a review about the future
Leonard Naymagon et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Guidelines for determination of the number of prior lines of therapy in multiple myeloma
S. Vincent Rajkumar et al.
BLOOD (2015)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S. K. Kumar et al.
LEUKEMIA (2014)
Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets
Ben van Hout et al.
VALUE IN HEALTH (2012)
Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study
Ingemar Turesson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire
Madeleine T. King et al.
PATIENT-RELATED OUTCOME MEASURES (2010)
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
R. A. Kyle et al.
LEUKEMIA (2009)
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
A. Simon Pickard et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
分享论文
